This dataset contains summary data visualizations and clinical data from a broad sampling of 184 pancreatic adenocarcinomas and patients. The data was gathered as part of the PanCancer Atlas initiative, which aims to answer big, overarching questions about cancer by examining the full set of tumors characterized in the robust TCGA dataset. The clinical data includes mutation count, information about...

This dataset contains summary data visualizations and clinical data from the targeted sequencing of 10,000 clinical cases using the MSK-IMPACT assay. The clinical data includes mutation count, information about mutated genes, tumor mutational burden calculations, tissue site from which the sample was derived, tumor purity among other relevant data points. The data set also includes copy-number segment...

This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble...

TCGA Pancreatic Adenocarcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 186 carcinomas from 185 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information...

Dataset Description from EGA: "Sequencing of untreated pancreatic cancer metastases and primary tumor sections. " Abstract from the MSK Synapse article to further understand the dataset in EGA: "The extent of heterogeneity among driver gene mutations present in naturally occurring metastases-that is, treatment-naive metastatic disease-is largely unknown. To address this issue, we carried out 60x...

Study Description from the dbGaP: "Within the framework of the NCI-sponsored Cohort Consortium, investigators from 12 prospective epidemiologic cohorts formed the Pancreatic Cancer Cohort Consortium in 2006. This study, also known as "PanScan", is funded by the National Cancer Institute (NCI) and involves conducting a genome-wide association study (GWAS) of common genetic variants to identify markers...

Study Description from the dbGaP: "Pancreatic cancer is the 4th leading cause of cancer death in the United States. This is in large part due to the rapidly fatal course of this disease, as the vast majority of patients die within months of diagnosis and the five-year survival rate is less than 5. We have brought together over 8000 participants from 9 studies of pancreatic cancer, to conduct a GWAS...

Summary from the GEO: "Pancreatic adenosquamous carcinoma (PASC) is an aggressive cancer whose mutational origins are poorly understood. An early study reported high-frequency somatic mutations affecting UPF1, a core nonsense-mediated mRNA decay (NMD) factor, in PASC, but subsequent studies did not observe these lesions. The corresponding controversy about whether UPF1 mutations are important contributors...

Description from the BioProject: "In this study, whole genome sequencing and whole exome sequencing were performed to detect the genomic features of the pancreatic adenosquamous carcinoma." 125 samples were deposited and sequenced in this submission.

Summary from GEO: "Damaged tissues have increased risk of cancer development through poorly understood mechanisms. For example, in the pancreas, tissue damage collaborates with activating mutations in the Kras oncogene to dramatically accelerate the formation of early neoplastic lesions and, ultimately, pancreatic cancer. By integrating genomics, single-cell chromatin assays and spatiotemporally-controlled...